Evidence map›Paper›PMID 35601162›Full record

ArticleInternational journal of ophthalmology2022

Neuroretinal dysfunction in patients affected by neurofibromatosis type 1.

Antonietta Moramarco, Luca Lucchino, Fabiana Mallone, Michela Marcelli, Ludovico Alisi, Vincenzo Roberti, Sandra Giustini, Alessandro Lambiase, Marcella Nebbioso

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Antonietta MoramarcoDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Luca LucchinoDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Fabiana MalloneDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Michela MarcelliDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Ludovico AlisiDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Vincenzo RobertiDepartment of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Sandra GiustiniDepartment of Dermatology and Venereology, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Alessandro LambiaseDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Marcella NebbiosoDepartment of Sense Organs, Sapienza University of Rome, Policlinico Umberto I, Rome 00161, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo examine neuroretinal function by using the multifocal electroretinography (mfERG) test in patients with neurofibromatosis type 1 (NF1) without optic pathway gliomas (OPGs).

methodsThis study was conducted on 35 patients (35 eyes) with NF1 and 30 healthy subjects (30 eyes) for the control group. Each subject underwent a complete ophthalmological examination including spectral domain-optical coherence tomography (SD-OCT) and mfERG. The 1.5-Tesla magnetic resonance imaging (MRI) scan of the brain was performed in NF1 patients to assess the presence of OPGs. All participants were recruited having a best corrected visual acuity (BCVA) of no less than 20/20 in each eye. The amplitude and implicit time of the P1 wave (first-order Kernel component) were evaluated on mfERG. Data analysis was carried out in the two central degrees and in the four quadrants from two to 25 degrees of visual field.

resultsStatistically significant results were obtained for the P1 wave amplitudes in the 4 quadrants in NF1 patients compared to healthy controls, while the reduction was not significant in the 2 central degrees between the groups. A statistically significant difference was observed among the P1 wave amplitudes as recorded in the 4 quadrants within the NF1 group, with lower amplitudes detected in the nasal quadrants. No differences in the implicit times were recorded in the 2 central degrees and in the 4 quadrants as compared between NF1 patients and controls.

conclusionImpaired neuroretinal function in NF1 patients is expressed in a decreased amplitude of the P1-wave between 2 and 25 central retinal degrees on mfERG. Altered intracellular signal transduction due to abnormal neurofibromin-mediated cyclic adenosine monophosphate (cAMP) generation, can be involved. The possible use of mfERG as subclinical retinal damage indicator has a potential utility in clinical practice for the follow-up of NF1 patients.

Indexed as

multifocal electroretinographyneurofibromatosis type 1neurofibrominneuroretinal functionoptic pathway gliomas

Identifiers

PMID35601162
PMCPMC9091878
OpenAlexW4285744289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.